Partner Jack Lord was quoted in a Business Insurance article, “Employers Likely to Prevail in LGBT Cases at Supreme Court with Kennedy Retirement,” about whether employers will have an easier time combating sexual orientation discrimination claims before the U. S. Supreme Court in a post-Justice Anthony Kennedy court. The Supreme Court is likely to consider issues involving sexual orientation and gender discrimination due to a split among the circuits.
“That issue is going to go before the Supreme Court for sure in the next year or two,” Lord said. “If Justice Kennedy had stayed, I think odds are it would have been a 5 to 4 ruling saying that Title VII sex (discrimination) also includes gender identity and sexual orientation discrimination. I think now it’s going to be a 5-4 decision, but the other way.”
(Subscription required.)
“That issue is going to go before the Supreme Court for sure in the next year or two,” Lord said. “If Justice Kennedy had stayed, I think odds are it would have been a 5 to 4 ruling saying that Title VII sex (discrimination) also includes gender identity and sexual orientation discrimination. I think now it’s going to be a 5-4 decision, but the other way.”
(Subscription required.)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”